The Federal Trade Commission declined to investigate how the business practices of pharmacy benefit managers affect drug prices.

In a split 2–2 vote, the FTC failed to get the majority needed on Monday to approve a motion to study the pharmacy benefit manager industry, which is responsible for negotiating drug prices with pharmaceutical companies. Critics argue pharmacy benefit managers have been responsible for increased list prices for drugs.